Scarica l'app Stockscreener
34.97
0.85%
-0.30
Dopo l'orario di chiusura:
34.93
-0.04
-0.11%
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
TYRA Initiates Coverage On by Guggenheim -- Price Target Announced at $54.00 - GuruFocus
This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $54 - 富途牛牛
Guggenheim Initiates Tyra Bioscience at Buy With $54 Price Target - marketscreener.com
Guggenheim Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
TYRA (Nasdaq) Form 144: Director reports two 8,000-share transactions - Stock Titan
The Technical Signals Behind (TYRA) That Institutions Follow - Stock Traders Daily
Growth Stocks To Watch Today – April 10th - Defense World
JPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRA - MarketBeat
IPO Launch: Is Tyra Biosciences Incs ROE strong enoughEntry Point & Precise Swing Trade Alerts - baoquankhu1.vn
FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Tyra Biosciences (NASDAQ:TYRA) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target - marketscreener.com
CCORF Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
Canaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN
Growth Stocks To Watch Now – April 3rd - Defense World
A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress - Yahoo Finance
Promising Growth Stocks To Watch Today – April 2nd - Defense World
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com
Tyra Bioscience Strengthens Financial Leadership with New Officer - TipRanks
Tyra Biosciences (TYRA) VP details multi-year stock option grants - Stock Titan
Tyra Biosciences names Julia Rueb principal accounting officer, succeeding Alan Fuhrman - TradingView — Track All Markets
Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer - Stock Titan
Tyra Biosciences, Inc. Announces Principal Accounting Officer Changes, Effective April 1, 2026 - marketscreener.com
Tyra Biosciences stock hits all-time high at 39.21 USD By Investing.com - Investing.com South Africa
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Growth Stocks Worth Watching – March 31st - Defense World
Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year HighWhat's Next? - MarketBeat
Tyra Biosciences stock hits all-time high at 39.21 USD - Investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading 9.8% HigherShould You Buy? - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - MSN
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock - MarketBeat
Tyra Biosciences director Kaplan sells shares worth $528k By Investing.com - Investing.com India
Tyra Biosciences director Kaplan sells shares worth $528k - Investing.com
Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares - Stock Titan
Insider plans sale of 53,172 TYRA shares via option exercise (TYRA) - Stock Titan
Piper Sandler reiterates Tyra Biosciences stock rating on oral therapy potential - Investing.com Canada
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Highs Report: Is Tyra Biosciences Inc forming a breakout patternChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Non Muscle Invasive Bladder Cancer Pipeline Expands As 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds Delveinsight CG Oncology, Janssen, Tyra Biosciences, Urogen Pharma - Mena FN
Dabo gratinib designation honors key Tyra Biosciences executives - tradersunion.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5%Should You Sell? - MarketBeat
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - Sahm
Best Growth Stocks To Follow Today – March 20th - Defense World
Piper Sandler Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $56.00 - Defense World
Technical Reactions to TYRA Trends in Macro Strategies - Stock Traders Daily
Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - Sahm
Cantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendation - MSN
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position - AOL.com
Boone Capital Invests in Tyra Biosciences: $10.48M Stake AcquiredNews and Statistics - IndexBox
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):